Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Pharmaceutical Design|May 18, 2012
Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigenRenee Vermeij, Ninke Leffers, Cornelis J Melief, et al.
Expert Review of Vaccines|June 23, 2011
Vaccine-based clinical trials in ovarian cancerNinke Leffers, Toos Daemen, H Marike Boezen, et al.
The Cochrane Database of Systematic Reviews|January 22, 2010
Antigen-specific active immunotherapy for ovarian cancerNinke Leffers, Toos Daemen, Wijnand Helfrich, et al.
The Cochrane Database of Systematic Reviews|September 18, 2014
Antigen-specific active immunotherapy for ovarian cancerNinke Leffers, Toos Daemen, Wijnand Helfrich, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2011
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytesMarloes Gooden, Margit Lampen, Ekaterina S Jordanova, et al.
Gynecologic Oncology|June 24, 2008
Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulationNinke Leffers, Annechien J A Lambeck, Pauline de Graeff, et al.
The Cochrane Database of Systematic Reviews|September 11, 2018
Antigen-specific active immunotherapy for ovarian cancerSterre T Paijens, Ninke Leffers, Toos Daemen, et al.
Clinical & Developmental Immunology|October 2, 2010
Potential target antigens for a universal vaccine in epithelial ovarian cancerRenee Vermeij, Toos Daemen, Geertruida H de Bock, et al.
Gynecologic Oncology|February 27, 2009
Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancerNinke Leffers, Marloes J M Gooden, Anna A Mokhova, et al.
International Journal of Cancer|February 18, 2011
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancerNinke Leffers, Renee Vermeij, Baukje-Nynke Hoogeboom, et al.
Pageof 2